CAS Number: 122384-88-7Molecular Weight: 3902.89Salt Form: TFAPurity: >95%Sequence (3-letter): Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Cys2-Cys7)Sequence (1-letter): KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-NH2Storage: -20 °C or belowSolubility: water 5 mg/ml

Amylin (1-37), human, also known as Islet Amyloid Polypeptide (IAPP) is the primary component of amyloid deposits found in pancreatic B-cells of patients with type two diabetes mellitus. Amyloid deposition contributes to the pathology of a variety of disorders, including Alzheimer’s disease, chronic renal dialysis, senile cardiac amyloidosis and type two diabetes mellitus. Amyloid has been proposed to modulate glucose metabolism in conjunction with insulin, but in patients with type two diabetes mellitus, amylin aggregates to form amyloid.

References

1. Castillo et al (1995) “Amylin/islet polypeptide: biochemistry, physiology, patho-physiology” Diabete Metab. 21 (1): 3-25. 2.Schmitz et al (2004) “Amylin agonists: a novel approach in the treatment of diabetes” Diabetes 53 Supple 3: S233-238.3. Hoogwerf et al (2008) “Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk” Vasc.Health Risk Manag. 4 (2): 355-362.